Celldex Therapeutics (CLDX) News Today $22.46 -0.13 (-0.58%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$22.50 +0.04 (+0.18%) As of 02/21/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Celldex Therapeutics (CLDX) Projected to Post Earnings on MondayFebruary 22 at 1:25 AM | americanbankingnews.comAnalysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price at $60.22February 19 at 1:13 AM | americanbankingnews.comCelldex Therapeutics (CLDX) Expected to Announce Quarterly Earnings on MondayCelldex Therapeutics (NASDAQ:CLDX) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports.February 17, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from Analysts at UBS GroupFebruary 16, 2025 | americanbankingnews.comEquities Analysts Offer Predictions for CLDX Q1 EarningsFebruary 16, 2025 | americanbankingnews.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, six have aFebruary 16, 2025 | marketbeat.comBrokers Issue Forecasts for CLDX Q1 EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Celldex Therapeutics in a note issued to investors on Thursday, February 13th. Leerink Partnrs analyst T. Smith anticipates that the biopharmaceutical company will post earnFebruary 15, 2025 | marketbeat.comTSP Capital Management Group LLC Has $5.64 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)TSP Capital Management Group LLC lessened its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 9.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 223,343 sFebruary 15, 2025 | marketbeat.comKynam Capital Management, LP Increases Stake in Celldex Therapeutics IncFebruary 15, 2025 | gurufocus.comUBS Initiates Coverage of Celldex Therapeutics (CLDX) with Buy RecommendationFebruary 14, 2025 | msn.comCelldex initiated with a Buy at UBSFebruary 13, 2025 | markets.businessinsider.comUBS Group Initiates Coverage on Celldex Therapeutics (NASDAQ:CLDX)UBS Group began coverage on Celldex Therapeutics in a research note on Thursday. They set a "buy" rating and a $44.00 price target for the company.February 13, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Sets New 1-Year Low - What's Next?Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week Low - What's Next?February 13, 2025 | marketbeat.comFMR LLC Reduces Stake in Celldex Therapeutics IncFebruary 12, 2025 | gurufocus.comCelldex stock touches 52-week low at $20.99 amid market challengesFebruary 11, 2025 | msn.comSovran Advisors LLC Buys New Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Sovran Advisors LLC purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 113,457 shares of the biopharmacFebruary 11, 2025 | marketbeat.comCelldex Therapeutics: Will They Get It Right After A Decade Of Failures?February 10, 2025 | seekingalpha.comCelldex Therapeutics (NASDAQ:CLDX) Reaches New 52-Week Low - Here's What HappenedCelldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month Low - Here's WhyFebruary 7, 2025 | marketbeat.comEquities Analysts Set Expectations for CLDX FY2025 EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for Celldex Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will post earnings oFebruary 7, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for CLDX FY2028 Earnings?Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2028 EPS estimates for shares of Celldex Therapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical companyFebruary 6, 2025 | marketbeat.comDemystifying Celldex Therapeutics: Insights From 6 Analyst ReviewsJanuary 31, 2025 | benzinga.comCelldex Therapeutics' SWOT analysis: barzolvolimab drives stock outlookJanuary 30, 2025 | msn.comCelldex Therapeutics (NASDAQ:CLDX) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday.January 29, 2025 | marketbeat.comCelldex Therapeutics' SWOT analysis: barzolvolimab drives stock potentialJanuary 23, 2025 | msn.comCantor Fitzgerald Forecasts CLDX FY2025 EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical compaJanuary 22, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by BrokeragesCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, five have assigned aJanuary 22, 2025 | marketbeat.comShort Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expands By 10.7%Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 8,090,000 shares, an increase of 10.7% from the December 15th total of 7,310,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is presently 8.0 days.January 19, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month Low - Here's What HappenedCelldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month Low - Here's WhyJanuary 13, 2025 | marketbeat.comBuy Rating for Celldex: Strategic Market Position and Growth Potential Amid Jasper’s Delayed CompetitionJanuary 9, 2025 | markets.businessinsider.comCelldex Therapeutics (NASDAQ:CLDX) Shares Gap Up - Here's WhyCelldex Therapeutics (NASDAQ:CLDX) Shares Gap Up - Should You Buy?January 8, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Sees Significant Drop in Short InterestCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 7,310,000 shares, a drop of 5.1% from the November 30th total of 7,700,000 shares. Based on an average daily volume of 1,210,000 shares, the days-to-cover ratio is presently 6.0 days.January 1, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, five have assignedDecember 28, 2024 | marketbeat.comBarclays PLC Increases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Barclays PLC boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 140.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 130,381 shares of the biopharmaceutical company's stocDecember 22, 2024 | marketbeat.comCelldex Therapeutics, Inc.: Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic DermatitisDecember 20, 2024 | finanznachrichten.deCelldex initates Phase 2 study of barzolvolimab in ADDecember 20, 2024 | markets.businessinsider.comWhat Analysts Are Saying About Celldex Therapeutics StockDecember 20, 2024 | benzinga.comCelldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Thursday.December 19, 2024 | marketbeat.comCelldex Therapeutics Inc (CLDX) Launches Phase 2 Study of Barzolvolimab for Atopic DermatitisDecember 19, 2024 | gurufocus.comCelldex Initiates Phase 2 Study of Barzolvolimab in Atopic DermatitisDecember 19, 2024 | globenewswire.comState Street Corp Sells 173,932 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)State Street Corp decreased its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 6.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,485,156 shares of the biopharmaceutical company's stock after selling 17December 17, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Trading Down 5.5% - Should You Sell?Celldex Therapeutics (NASDAQ:CLDX) Trading Down 5.5% - Time to Sell?December 13, 2024 | marketbeat.comBNP Paribas Financial Markets Purchases 21,013 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)BNP Paribas Financial Markets raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 293.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,181 shares of the biopharmaceutical cDecember 11, 2024 | marketbeat.comXTX Topco Ltd Makes New $1.56 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)XTX Topco Ltd acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 45,917 shares of the biopharmaceutical company's stockDecember 9, 2024 | marketbeat.comWellington Management Group LLP Buys 1,167,659 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Wellington Management Group LLP boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 14.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,243,599 sharDecember 8, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Sells 24,010 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)The Manufacturers Life Insurance Company lessened its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 18.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 105,777 shares of the biopharmaceutical company'sDecember 8, 2024 | marketbeat.comReadystate Asset Management LP Makes New $6.10 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Readystate Asset Management LP acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 179,518 shares of the biopharmaceutical company's stock, valued at apDecember 5, 2024 | marketbeat.comRedmile Group LLC Has $22.34 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Redmile Group LLC lessened its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 8.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 657,175 shares of the biopharmaceutical compDecember 5, 2024 | marketbeat.comCinctive Capital Management LP Reduces Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Cinctive Capital Management LP cut its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 62.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 33,797 shares of the biopharmaceutical company's stock after selling 57,330 shDecember 4, 2024 | marketbeat.comFmr LLC Has $204.77 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Fmr LLC trimmed its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 23.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,024,416 shares of the biopharmaceutDecember 3, 2024 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has received an average rating of "Moderate Buy" from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buDecember 3, 2024 | marketbeat.com Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Media Mentions By Week CLDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼0.670.60▲Average Medical News Sentiment CLDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼104▲CLDX Articles Average Week Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alkermes News Ionis Pharmaceuticals News Amicus Therapeutics News Ligand Pharmaceuticals News BioCryst Pharmaceuticals News Dynavax Technologies News Geron News MannKind News Myriad Genetics News Novavax News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
